Changes to the Code
S. 2710 · Open Payments Expansion Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
42 U.S.C. § 1320a–7h Transparency reports and reporting of physician ownership or investment interests
2 changes the bill asks for here, 2 carried out
- Carried out:
in subsection (a), by adding at the end the following new paragraph:
(3) Donations to patient advocacy organizations.— (A) In general.— In addition to the requirements under paragraphs (1) and (2), on March 31, 2027, and on the 90th day of each calendar year beginning thereafter, any applicable manufacturer or applicable group purchasing …
- Carried out:
in subsection (c)(1)(C)(ix), by striking
or covered recipient
each place it appears and insertingcovered recipient, or patient advocacy organization
.
§ 1320a–7h(a)–(b)
Start of § 1320a–7h to (a)(2)(B) unchanged ·
(C) Any payment or other transfer of value provided to a physician holding such an ownership or investment interest (or to an entity or individual at the request of or designated on behalf of a physician holding such an ownership or investment interest), including the information described in clauses (i) through (viii) of paragraph (1)(A), except that in applying such clauses, “physician” shall be substituted for “covered recipient” each place it appears.
(D) Any other information regarding the ownership or investment interest the Secretary determines appropriate.
(3) [inserted: Donations to patient advocacy organizations.—]
(A) [inserted: In general.—] [inserted: In addition to the requirements under paragraphs (1) and (2), on March 31, 2027, and on the 90th day of each calendar year beginning thereafter, any applicable manufacturer or applicable group purchasing organization shall submit to the Secretary, in such electronic form as the Secretary shall require, details regarding any covered payment made by such manufacturer or organization to any patient advocacy organization, including—]
(i) [inserted: the name of the patient advocacy organization; and]
(ii) [inserted: the amount of the covered payment.]
(B) [inserted: Definitions.—] [inserted: In this paragraph:]
(i) [inserted: Covered payment.—] [inserted: The term “covered payment” means any—]
(I) [inserted: payment or other transfer of value; or]
(II) [inserted: indirect payment or other transfer of value.]
(ii) [inserted: Indirect payment or other transfer of value.—] [inserted: The term “indirect payment or other transfer of value” means a payment or other transfer of value made by an applicable manufacturer or applicable group purchasing organization to a patient advocacy organization through a third party, where the applicable manufacturer or applicable group purchasing organization requires, instructs, directs, or otherwise causes the third party to provide the payment or transfer of value, in whole or in part, to a patient advocacy organization.]
(iii) [inserted: Patient advocacy organization.—] [inserted: The term “patient advocacy organization” means an organization described in section 501(c)(3) of the Internal Revenue Code of 1986 that is exempt from taxation under section 501(a) of such Code that—]
(I) [inserted: provides education, advocacy, and support services oriented towards patients and caregivers;]
(II) [inserted: is concerned with a medical condition diagnosed by a licensed medical practitioner who is in good standing with a State licensing body; or]
(III) [inserted: has a mission that seeks to help vulnerable individuals affected by medical conditions or to help the families of such vulnerable individuals and takes actions consistent with such mission.]
(b) Penalties for noncompliance
(1) Failure to report
(A) In general Subject to subparagraph (B) except as provided in paragraph (2), any applicable manufacturer or applicable group purchasing organization that fails to submit information required under subsection (a) in a timely manner in accordance with rules or regulations promulgated to carry out such subsection, shall be subject to a civil money penalty of not less than $1,000, but not more than $10,000, for each payment or other transfer of value or ownership or investment interest not reported as required under such subsection. Such penalty shall be imposed and collected in the same manner as civil money penalties under subsection (a) of section 1320a–7a of this title are imposed and collected under that section.
§ 1320a–7h(c)(1)In general(C)–(E)
(b)(1)(B)–(c)(1)(C) unchanged ·
(viii) in the case of information made available under this subparagraph prior to January 1, 2022, does not contain the National Provider Identifier of the covered recipient, and
(ix) subject to subparagraph (D), provides the applicable manufacturer, applicable group purchasing organization, [struck: or ]covered recipient[inserted: ,] [inserted: or patient advocacy organization ]an opportunity to review and submit corrections to the information submitted with respect to the applicable manufacturer, applicable group purchasing organization, [struck: or ]covered recipient, [inserted: or patient advocacy organization, ]respectively, for a period of not less than 45 days prior to such information being made available to the public.
(D) Clarification of time period for review and corrections In no case may the 45-day period for review and submission of corrections to information under subparagraph (C)(ix) prevent such information from being made available to the public in accordance with the dates described in the matter preceding clause (i) in subparagraph (C).
(E) Delayed publication for payments made pursuant to product research or development agreements and clinical investigations
Rest of § 1320a–7h unchanged ·